Search clinical trials for: Flu Vaccine

Total 28267 results

MedImmune LLC
AstraZeneca

Completed

Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2017-2018 Season (FluMist)

Healthy | Influenza

United States
Johns Hopkins Bloomberg School of Public Health
Centers for Disease Control and Prevention

Completed

Immune and Hormone Response to Influenza Vaccine

Healthy

United States
Eurocine Vaccines AB

Completed

Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose™ FLU in Older Adults

Influenza

Sweden
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Innate and Acquired Immunity to Influenza Infection and Immunization (SLVP029)

Influenza

United States
Emory University

Completed

The Immunologic Basis for an Attenuated Immune Response to the Influenza Vaccine After Repeated Annual Vaccination (FLU1)

Influenza

United States
MedImmune LLC
AstraZeneca

Completed

Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age (FluMist)

Healthy | Influenza

United States
National Institute of Allergy and Infectious Diseases...
The Emmes Company, LLC

Completed

Seasonal Influenza DNA Vaccine & Seasonal Influenza Trivalent Inactivated Vaccine (TIV) in Children & Adolescents

Influenza

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer

Prostate Cancer

United States
Vaccitech (UK) Limited
University of Oxford

Terminated

Improved Novel VaccIne CombinaTion InflUenza Study (INVICTUS)

Influenza

United Kingdom
Merck Sharp & Dohme LLC

Completed

Study to Evaluate Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants ≥50 Years of Age (V211-062)

Herpes Zoster
McMaster University
Canadian Institutes of Health Research (CIHR)

Completed

Live Versus Inactivated Influenza Vaccine Study in Hutterite Children

Influenza

Canada
GlaxoSmithKline

Completed

Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Children

Influenza

Spain
GlaxoSmithKline

Completed

Study on the Incidence of Influenza and Its Complications, in Subjects Aged 50 Years and Over Vaccinated With Fluarix™

Influenza

United States, Germany, Poland, Netherlands
Indonesia University

Completed

Probiotic and Influenza Vaccination to Reducing Influenza-like Illness Incident in Elderly

Influenza-like Illness

Indonesia
Walter Reed Army Medical Center
University of Michigan; University of Texas; University of South Alabama; Scripps...

Completed

FluMist in Egg Allergic Patients (FluEMIST)

Egg Allergy | Eligible for Vaccination Against Influenza

United States
University of Campinas, Brazil

Completed

Triclosan as Adjunctive Therapy in the Plaque Control in Children From Generalized Aggressive Periodontitis Families.

Generalized Aggressive Periodontitis

Brazil
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Trastuzumab, Cyclophosphamide, and Vaccine Therapy in Treating Patients With High-Risk or Metastatic Breast Cancer

Breast Cancer

United States
GlaxoSmithKline

Completed

An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children

Influenza

Spain, Poland, Philippines, Thailand, Belgium, United Kingdom, Czechia, Bangladesh, Dominican Republic, Honduras, Lebanon, Turkey, India
GlaxoSmithKline

Completed

Lot Consistency, Immuno, Safety of Meningococcal Vaccine GSK134612 Given With Fluarix™ to 18-55 Year-Old Adults

Infections, Meningococcal

Philippines, Lebanon
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of Fluarix™ Vaccine in Children Who Have Previously Been Vaccinated With Pandemrix™

Influenza

Sweden, Netherlands
GlaxoSmithKline

Completed

A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Adults

Influenza

Germany
GlaxoSmithKline

Completed

Safety and Immunogenicity Study of GSK Biologicals' Seasonal Influenza Candidate Vaccine (GSK2321138A)

Influenza

Germany, Spain, United States, Korea, Republic of, Romania, Taiwan
GlaxoSmithKline

Completed

Trial to Evaluate the Safety and the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in Healthy Children

Influenza

Spain
GlaxoSmithKline

Completed

A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Adults

Influenza

United States, Canada, Mexico
GlaxoSmithKline

Completed

A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Children

Influenza

Spain, Taiwan, Canada, United States, Mexico
GlaxoSmithKline

Completed

Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children

Influenza

United States
GlaxoSmithKline

Completed

Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged 18-64 Years

Influenza

United States, Canada
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children

Influenza

United States, Germany, Philippines, Czechia, France
GlaxoSmithKline

Completed

Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine in Elderly People

Influenza

Germany, Sweden, Netherlands
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of a GlaxoSmithKline Biologicals' Candidate Influenza Vaccine in Healthy Children

Influenza

Mexico
M.D. Anderson Cancer Center
Celgene Corporation

Terminated

Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL)

Hematologic Disorder

United States
University of Florida
Colgate Palmolive

Completed

Periodontal Treatment Response in Type II Diabetic Patients

Periodontal Disease | Type II Diabetes

United States
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine When Administered in Children Who Previously Participated in Study 115345

Influenza

Spain, Czechia, United Kingdom, Poland
GlaxoSmithKline

Completed

A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older

Influenza

Canada
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Trivalent Split Virion Influenza Vaccine Fluviral™ (2013-2014 Season) in Adults Aged 18 Years and Older

Influenza

Canada
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine, Fluarix®/Influsplit SSW® (2013/2014 Season), in Adults 18 Years of Age and Older

Influenza

Germany
GlaxoSmithKline

Completed

Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) Compared to Fluzone® Quadrivalent in Children 6 to 35 Months of Age

Influenza

United States, Mexico
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine, Fluarix/Influsplit Tetra® (2013/2014 Season), in Adults 18 Years of Age and Older

Influenza

Germany
GlaxoSmithKline

Completed

Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children From 6 to 35 Months of Age

Influenza

United States
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of FluarixTM Vaccine in Children Who Have Previously Been Vaccinated With PandemrixTM

Influenza

Finland
GlaxoSmithKline

Completed

Immunogenicity and Safety of PrepandrixTM in Korean Subjects Aged 18 to 60 Years Old

Influenza

Korea, Republic of
Washington University School of Medicine
National Cancer Institute (NCI)

Terminated

Response to Influenza Vaccine in Patients With Non-Hematologic Malignancies Receiving Chemotherapy

Neoplasms

United States
Public Health England
Royal Free and University College Medical School

Completed

Response of Older Adults to Influenza Vaccination With Regard to Cytomegalovirus (CMV) Status (CMVflu)

Influenza

United Kingdom
GlaxoSmithKline

Completed

Safety and Immune Response of Candidate H1N1 Influenza Vaccine GSK2340274A Following Seasonal Influenza Vaccination in Adults

Influenza

United States
GlaxoSmithKline

Completed

Immunogenicity and Safety of Vaccine GSK2340272A (H1N1) and GSK Biologicals Fluarix™ Vaccine When Co-administered in Elderly

Influenza

Sweden
GlaxoSmithKline

Completed

Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine for the Elderly

Influenza

Estonia, Slovakia
GlaxoSmithKline

Completed

Evaluation of Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Years and Older

Influenza

Germany, Sweden, Netherlands
GlaxoSmithKline

Completed

Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)

Influenza

Germany
GlaxoSmithKline

Completed

Clinical Study in Children, 6 Months to 3 Years of Age, to Assess Two Dose Levels of an Experimental Flu Vaccine, Using a Licensed Influenza Virus Vaccine, Vaxigrip® as the Control

Influenza

Canada
brian.ward
MedTeq; MEDICAL INTERNATIONAL TECHNOLOGIES (MIT CANADA) INC.

Completed

Comparison of Routine IM Influenza Immunization and Administration by Jet-injector (Med-Jet H4™) in Healthy Young Adults (Med-Jet H4™)

Needle Phobia

Canada

3

Subscribe